Samsung Bioepis Partners with Phrontline to Develop Next-Generation Dual-Payload ADCs for Cancer Treatment
Key Insights
Samsung Bioepis (search) and Phrontline Biopharma (search) have entered a global collaboration to co-develop two investigational antibody-drug conjugate assets, including TJ108 (search), targeting EGFR (search) and HER3 (search) receptors overexpressed in various cancers.
The partnership introduces bispecific, dual-payload ADC therapeutics designed to overcome limitations of current single-payload, single-target ADCs, particularly addressing resistance, tumor heterogeneity, and durability challenges.
Samsung Bioepis (search) will receive exclusive licensing rights for a topoisomerase-1 inhibitor (search) payload and expand its oncology portfolio beyond biosimilars into innovative drug development.
Samsung Bioepis (search) Co., Ltd. and Phrontline Biopharma (search) have announced a global strategic partnership to develop, manufacture, and commercialize two investigational antibody-drug conjugate (ADC) assets targeting solid tumors (search). The collaboration marks Samsung Bioepis' expansion beyond biosimilars into innovative oncology therapeutics, focusing on next-generation bispecific, dual-payload ADCs designed to address current treatment limitations.
Partnership Structure and Financial Terms
Under the agreement, Phrontline will receive an upfront payment and be eligible for additional milestone payments tied to development and regulatory achievements. Samsung Bioepis (search) will gain exclusive licensing rights to develop, manufacture, and commercialize two ADC assets: TJ108 (search) and another asset to be named. Additionally, Samsung will receive an exclusive license from Phrontline for one topoisomerase-1 inhibitor (search) (TOP1i) payload for application across its ADC pipeline.
TJ108: Dual-Target, Dual-Payload Innovation
The lead asset, TJ108 (search), represents a significant advancement in ADC technology as a bispecific, dual-payload conjugate targeting both Epidermal Growth Factor Receptor (EGFR (search)) and Human Epidermal Growth Factor Receptor 3 (HER3 (search)). These targets are overexpressed in a variety of cancers and contribute to aggressive growth and metastasis. TJ108 combines TOP1i and tubulin inhibitor payloads, delivering two complementary mechanisms of action through Phrontline's proprietary dual-linker payload (DLP) platform.
The DLP platform enables simultaneous delivery of two payloads with balanced potency through a branched-linker architecture while supporting scalable and efficient one-step conjugation. This approach is designed to address resistance, heterogeneity, and durability challenges that limit current single-payload, single-target ADCs.
Strategic Vision and Market Positioning
"We are excited to partner with Phrontline in developing and advancing differentiated ADCs that target a broad range of indications," said Kyung-Ah Kim, President and Chief Executive Officer at Samsung Bioepis (search). "We will continue to explore new business opportunities to address unmet needs of patients, leveraging our proven development platforms."
Zhaoyuan 'Tony' Chen, Founder and Chief Executive Officer of Phrontline Biopharma (search), emphasized the partnership's potential: "This partnership accelerates our vision to establish bispecific, dual-payload ADCs as a new class of precision oncology medicines. Together with Samsung Bioepis (search), we will scale the DLP platform — beginning with TJ108 (search) — to address resistance, heterogeneity, and durability challenges that limit today's single-payload, single-target ADCs."
Expanding Therapeutic Portfolio
Samsung Bioepis (search) is strategically expanding its pipeline beyond biosimilars to fulfill its mission of broadening patient access to treatments in areas of unmet therapeutic needs. The company currently has four biosimilars for trastuzumab, bevacizumab, denosumab, and pembrolizumab under Phase I and III clinical trials. The ADC development represents entry into the innovative drug space with differentiated platform technologies targeting patients who are not responding to current ADC therapeutic options or have developed resistance.
"We are now entering the innovative drug space with differentiated ADC platform technologies to treat patients who are not responding to current ADC therapeutics options or have developed resistance," noted a Samsung Bioepis (search) spokesperson. "Technologies such as site-specific conjugation and stable linkers develop a more stable ADC molecule, thereby enhancing the safety profile."
The collaboration adds a new therapeutic class to Samsung Bioepis (search)' broad spectrum portfolio covering immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology, positioning the company to address complex cancer (search) treatment challenges through innovative bispecific ADC technology.